Company GENFIT Euronext Paris
Equities
FR0004163111
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
||
3.385 EUR | 0.00% |
Business Summary
The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Research and Development of Innovative Medicines and Diagnostic Solutions
100.0
%
| 20 | 100.0 % | 29 | 100.0 % | +41.45% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
France
100.0
%
| 20 | 100.0 % | 29 | 100.0 % | +41.45% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 56 | 18-04-30 |
Founder | 68 | 99-08-31 | |
Thomas Baetz
DFI | Director of Finance/CFO | 50 | 21-04-21 |
John Brozek
CTO | Chief Tech/Sci/R&D Officer | 47 | - |
Stefanie Magner
CMP | Compliance Officer | 43 | 15-12-31 |
Pascal Caisey
COO | Chief Operating Officer | 56 | 19-08-31 |
Carol L. Addy
CTO | Chief Tech/Sci/R&D Officer | 64 | 19-09-08 |
Meriam Kabbaj
CTO | Chief Tech/Sci/R&D Officer | 50 | 22-11-30 |
Dean Hum
CTO | Chief Tech/Sci/R&D Officer | 61 | 99-12-31 |
Investor Relations Contact | 47 | 14-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 21-03-03 | |
Founder | 68 | 99-08-31 | |
Founder | 52 | 99-09-14 | |
Director/Board Member | 82 | 06-10-17 | |
Catherine Larue
BRD | Director/Board Member | 68 | 17-06-15 |
Director/Board Member | 56 | 17-06-15 | |
Katherine Kalin
BRD | Director/Board Member | 61 | 20-07-06 |
Eric Baclet
BRD | Director/Board Member | 64 | 20-07-06 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 49,834,983 | 43,212,891 ( 86.71 %) | 0 | 86.71 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+26.70% | 44.96B | |
-0.69% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.39% | 26.08B | |
-21.69% | 19.03B | |
+6.45% | 12.75B | |
+27.56% | 12.06B | |
-3.29% | 11.75B |
- Stock Market
- Equities
- GNFT Stock
- Stock
- Company GENFIT